Exelixis, Inc. (NASDAQ:EXEL)‘s stock had its “hold” rating reaffirmed by investment analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Sunday.

Other equities research analysts have also issued research reports about the stock. TheStreet raised shares of Exelixis from a “c” rating to a “b-” rating in a report on Monday, August 7th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research report on Thursday, August 3rd. BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. SunTrust Banks, Inc. began coverage on shares of Exelixis in a research report on Thursday, July 13th. They issued a “buy” rating and a $33.00 target price on the stock. Finally, Cann reaffirmed a “hold” rating on shares of Exelixis in a research report on Thursday, July 20th. Five analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $25.57.

Shares of Exelixis (EXEL) opened at 26.24 on Friday. The stock has a 50 day moving average of $27.13 and a 200 day moving average of $23.24. Exelixis has a 12-month low of $10.04 and a 12-month high of $29.50. The company has a market cap of $7.71 billion, a price-to-earnings ratio of 132.53 and a beta of 1.97.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The firm had revenue of $99.01 million during the quarter, compared to analyst estimates of $85.27 million. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. Exelixis’s quarterly revenue was up 173.1% on a year-over-year basis. Equities research analysts predict that Exelixis will post $0.26 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/12/exelixis-inc-exel-rating-reiterated-by-oppenheimer-holdings-inc.html.

Institutional investors and hedge funds have recently modified their holdings of the company. First Quadrant L P CA acquired a new stake in shares of Exelixis during the second quarter worth about $144,000. Meeder Asset Management Inc. acquired a new stake in shares of Exelixis during the first quarter worth about $170,000. Atlantic Trust Group LLC acquired a new stake in shares of Exelixis during the first quarter worth about $216,000. Wetherby Asset Management Inc. acquired a new stake in shares of Exelixis during the second quarter worth about $218,000. Finally, Caxton Associates LP acquired a new stake in shares of Exelixis during the second quarter worth about $227,000. 79.20% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.